Home

Adrian Hepner

CIK 1637347 · Chief Medical Officer · last filed 2023-03-01

Adrian Hepner is a Chief Medical Officer who has filed 8 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for COYA, was dated Mar 1, 2023. Current disclosed insider exposure totals $43.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$43.8K

Companies

2

Total Filings

8

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O COYA THERAPEUTICS, INC.
5850 SAN FELIPE ST., SUITE 500
HOUSTON, TX 77057
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
COYA Chief Medical Officer 10,000 $4.38 $43.8K $0 2 2023-03-01
EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted EVP and Chief Medical Officer 48,784 $2.14 $104.4K $0 6 2020-01-27

Recent Filings

8 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-03-01 COYA Grant (A) — $0 EDGAR
2023-01-04 COYA Buy (P) +10,000 $0 EDGAR
2020-01-27 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Tax (F) −1,630 -$94.5K EDGAR
2020-01-07 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Mixed +23,185 -$46.8K EDGAR
2019-01-25 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Mixed +18,229 -$31.9K EDGAR
2018-01-09 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Grant (A) +9,000 $0 EDGAR
2017-01-06 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Grant (A) — $0 EDGAR
2016-01-05 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Grant (A) — $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.